Cellular Biomedicine Group (NASDAQ:CBMG) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.
Insider & Institutional Ownership
8.3% of Cellular Biomedicine Group shares are held by institutional investors. Comparatively, 87.5% of Biogen shares are held by institutional investors. 8.3% of Cellular Biomedicine Group shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Cellular Biomedicine Group and Biogen’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellular Biomedicine Group||$340,000.00||779.16||-$25.49 million||($1.78)||-8.78|
|Biogen||$12.27 billion||5.43||$2.54 billion||$21.81||15.17|
Biogen has higher revenue and earnings than Cellular Biomedicine Group. Cellular Biomedicine Group is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and price targets for Cellular Biomedicine Group and Biogen, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cellular Biomedicine Group||0||1||1||0||2.50|
Cellular Biomedicine Group currently has a consensus price target of $38.00, suggesting a potential upside of 143.28%. Biogen has a consensus price target of $381.31, suggesting a potential upside of 15.22%. Given Cellular Biomedicine Group’s higher probable upside, equities analysts clearly believe Cellular Biomedicine Group is more favorable than Biogen.
This table compares Cellular Biomedicine Group and Biogen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cellular Biomedicine Group||-10,133.88%||-47.52%||-44.44%|
Risk & Volatility
Cellular Biomedicine Group has a beta of 3.34, meaning that its stock price is 234% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Biogen beats Cellular Biomedicine Group on 10 of the 14 factors compared between the two stocks.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing; and Novartis to manufacture and supply the CAR-T cell therapy KymriahÂ. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.